MA55134A - Anticorps anti-staphylococcus et leurs utilisations - Google Patents

Anticorps anti-staphylococcus et leurs utilisations

Info

Publication number
MA55134A
MA55134A MA055134A MA55134A MA55134A MA 55134 A MA55134 A MA 55134A MA 055134 A MA055134 A MA 055134A MA 55134 A MA55134 A MA 55134A MA 55134 A MA55134 A MA 55134A
Authority
MA
Morocco
Prior art keywords
staphylococcus antibodies
staphylococcus
antibodies
Prior art date
Application number
MA055134A
Other languages
English (en)
French (fr)
Inventor
Alida Coppi
Christos Kyratsous
Brinda Prasad
Anna Zumsteg
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA55134A publication Critical patent/MA55134A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA055134A 2018-11-21 2019-11-20 Anticorps anti-staphylococcus et leurs utilisations MA55134A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862770608P 2018-11-21 2018-11-21
US201962822029P 2019-03-21 2019-03-21
US201962865436P 2019-06-24 2019-06-24

Publications (1)

Publication Number Publication Date
MA55134A true MA55134A (fr) 2021-09-29

Family

ID=68848487

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055134A MA55134A (fr) 2018-11-21 2019-11-20 Anticorps anti-staphylococcus et leurs utilisations

Country Status (16)

Country Link
US (2) US12024556B2 (https=)
EP (1) EP3883963A1 (https=)
JP (1) JP2022512904A (https=)
KR (1) KR20210093856A (https=)
CN (1) CN112867732A (https=)
AU (1) AU2019384790A1 (https=)
BR (1) BR112021005522A2 (https=)
CA (1) CA3110377A1 (https=)
CL (2) CL2021001307A1 (https=)
CO (1) CO2021003752A2 (https=)
IL (1) IL281056A (https=)
MA (1) MA55134A (https=)
MX (1) MX2021005863A (https=)
PH (1) PH12021550538A1 (https=)
SG (1) SG11202102060PA (https=)
WO (1) WO2020106814A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117106077B (zh) * 2022-04-28 2024-07-16 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
GB202311984D0 (en) * 2023-08-04 2023-09-20 Petmedix Ltd Optimised fc molecules
CN118580347B (zh) * 2024-05-13 2025-02-07 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌蛋白a的单克隆抗体及其应用
CN120943954B (zh) * 2025-10-20 2026-02-06 重庆原伦生物科技有限公司 抗金黄色葡萄球菌IsdB抗体的制备及其应用
CN120988116B (zh) * 2025-10-24 2025-12-30 重庆原伦生物科技有限公司 针对金黄色葡萄球菌IsdB的抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US7488807B2 (en) * 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2012122533A2 (en) * 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
WO2013096948A1 (en) * 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
PL3366705T3 (pl) 2012-09-12 2023-09-18 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TWI781130B (zh) * 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
CA3076632A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

Also Published As

Publication number Publication date
US12024556B2 (en) 2024-07-02
KR20210093856A (ko) 2021-07-28
BR112021005522A2 (pt) 2021-06-29
PH12021550538A1 (en) 2022-02-21
US20200157193A1 (en) 2020-05-21
CL2021001307A1 (es) 2021-11-05
WO2020106814A1 (en) 2020-05-28
CO2021003752A2 (es) 2021-04-19
AU2019384790A1 (en) 2021-03-18
CA3110377A1 (en) 2020-05-28
CN112867732A (zh) 2021-05-28
CL2023003084A1 (es) 2024-04-12
US20240301041A1 (en) 2024-09-12
IL281056A (en) 2021-04-29
JP2022512904A (ja) 2022-02-07
MX2021005863A (es) 2021-07-16
SG11202102060PA (en) 2021-03-30
EP3883963A1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
EP3891183A4 (en) ANTI-CLAUDIN ANTIBODIES AND USES THEREOF
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND USES THEREOF
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3918323A4 (en) ANTI-GAL3 ANTIBODIES AND USES THEREOF
EP3625263A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
EP3762030A4 (en) ANTI-CD73 ANTIBODIES AND USES THEREOF
EP3383916A4 (en) Anti-cd73 antibodies and uses thereof
EP3389702A4 (en) ANTI-LAG-3 ANTIBODIES AND USES THEREOF
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND USES THEREOF
EP3790586A4 (en) ANTI-DLL3 ANTIBODIES AND USES THEREOF
EP3645563A4 (en) ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3850012A4 (en) Anti-tnfrsf9 antibodies and uses thereof
EP3755714A4 (en) Anti-angiopoietin-2 antibodies and uses thereof
EP3894440A4 (en) ANTI-IL-27 ANTIBODIES AND USES THEREOF
EP3672987A4 (en) ANTI-APELIN ANTIBODIES AND USES THEREOF
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3962954A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
EP3768317A4 (en) ANTI-IL-27 ANTIBODIES AND USES THEREOF